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There are things known and things unknown and in between are the doors.
Jim Morrison
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ABSTRACT
The TRIM5α protein from rhesus macaques (TRIM5αrh) exhibits a remarkable
ability to potently inhibit infection by Human Immunodeficiency Virus Type-1 (HIV-1).
Extensive studies have shown that TRIM5α is capable of self-associating at many levels,
eventually leading to the formation of a hexameric assembly that can superimpose on the
hexameric lattice of the HIV-1 capsid. The mechanism underlying the self-association of
TRIM5α and the molecular determinants of self-association remain to be completely
understood. In this study, we show that the Linker 2 (L2) region of TRIM5rh is important
for dimerization and higher order self-association, both of which are independent
processes. Additionally, fluorescence resonance energy transfer (FRET) analysis suggests
that an antiparallel dimer configuration is the basic unit of TRIM5α, consistent with the
recently published crystal structure of the CCL2 region of TRIM25 by Sanchez et al. We
propose a homology model of the CCL2 fragment of TRIM5α based on the structure of
the TRIM25 CCL2 region. In this model the Helix 3 of the L2 region folds back onto
Helix 1 (CC domain), possibly ensuring correct binding of the SPRY domain to the HIV1 core. These studies reveal previously unknown determinants in the L2 region that
govern self-association of TRIM5α.

viii

CHAPTER 1
INTRODUCTION
Acquired Immunodeficiency Syndrome (AIDS) has taken over thirty-six million
lives since its discovery in 1981, and an additional 33.4 million people are currently
infected worldwide (CDC). AIDS, an immune system disease of humans, can be
characterized by a below average CD4+ T cell count. Once this occurs, the immune
system can no longer fight off infections and the body can succumb to opportunistic
pathogens. Human Immunodeficiency Virus Type 1 (HIV-1) is a lentivirus that can lead
to AIDS by infecting a variety of critical immune cells; including CD4+ T cells, dendritic
cells, and macrophages. This generally leads to fatality by overpowering the immune
system leading to AIDS.
HIV-1 Structure and Genome
HIV-1 is a lentivirus belonging to the retroviridae family that predominantly
infects CD4+ T helper cells as well as other immune cells such as macrophages.
Lentiviruses manifest slowly into disease and are capable of integrating into the host cell
genome as a provirus that can remain dormant for years in resting CD4+ memory T cells.
HIV-1 virions are about 100 nm in diameter and generally spherical, coated with a viral
envelope or membrane composed of phospholipids (Figure 1b). The virus carries two
copies of positive single-stranded RNA, approximately 10 kilobases in length, which
code for nine open reading frames (ORFs) and fifteen proteins (Figure 1a). The three
1

polyproteins, which can then be cleaved by the viral protease encoded within the Pol
polyprotein. Env is cleaved by the viral protease into two glycoproteins: the
transmembrane gp41 (TM) and gp120 (SU) located on the surface of the virion. These
function to bind to receptors on the infected cell to facilitate fusion of viral and cellular
membranes. During viral maturation, the viral protease cleaves Pol away from the GagPol precursor and then further cleaves the Pol polypeptide into three proteins: protease
(pro, p10), reverse transcriptase (RT, p50), and integrase (IN, p31). Pro is required to
cleave Gag and Gag-Pol polyproteins during virion maturation. RT makes a doublestranded DNA copy of the two genomic RNA strands, and encompasses RNase H activity
to eliminate the RNA strand from the first DNA strand, permitting generation of a
complementary strand of DNA (cDNA). IN mediates the insertion of the HIV-1 provirus
into the host cell genome through three critical functional enzymes: exonuclease,
endonuclease, and ligase. Gag is cleaved into four proteins: matrix (MA, p17), capsid
(CA, p24), nucleocapsid (NC, p9), and p6 that make up the viral core. MA lines the
interior of the viral membrane to increase virion stability. Assembled from 250 hexamers
and 12 pentamers, CA forms a hexameric lattice composed of about 1500 copies of CA
that help make up the conical core around the viral RNA[1, 2]. The NC forms a stable
complex with the viral RNA for protection. All of the above mentioned structural
proteins facilitate early events during infection.
In addition to structural proteins, HIV-1 also encodes regulatory proteins (Tat and
Rev) and accessory proteins (Vpu, Vpr, Vif, and Nef) that interact with the human host.
Tat is a transcriptional transactivator expressed early in infection that recognizes a

transactivator response element (TAR) in the 5’ hairpin structure of the viral RNA to
begin complex formation for transcription initiation. Rev is an RNA binding protein that
binds to the Rev response element (RRE) to regulate splicing and transport of viral RNA
by allowing unspliced transcripts to move from the nucleus to the cytoplasm for
translation and packaging of the virus. Vpu helps weaken interactions between viral
glycoproteins and host cellular receptors to assist in virus escape. Vpr has been shown to
facilitate the movement of the viral genome into the nucleus upon infection. Vif destroys
host cellular proteins to increase production of infectious virions. Finally, Nef is thought
to serve many purposes including: CD4 expression downregulation, perturbation of T cell
activation, and infectivity enhancement.

Figure 1: HIV-1 structure and genome. A) Genomic organization of the HIV-1
genome. B) Structural organization of an HIV-1 virion. Reprinted with permission from
[3].

HIV-1 Life Cycle
Viral Entry
The HIV-1 envelope spikes, gp41 and gp120, initiate viral entry into CD4+ T cells
or other immune cells expressing CD4 (macrophages and dendritic cells). A primary
interaction between gp120 and CD4 promotes conformational changes that expose
binding sites on gp120 for a second cell surface molecule known as chemokine receptor 5
(CCR5) (Figure 2-step 1)[4]. Subsequently, the fusion peptide that is part of the gp41 Nterminus is inserted into the host cell membrane to allow fusion between viral and
cellular membranes (Figure 2-step 2).
Uncoating
Uncoating is the process by which the viral core, which houses the
ribonucleoprotein (RNP) complex, begins to dissociate allowing the viral RNA to enter
the cytoplasm of the host cell (Figure 2-step 3). The exact details of uncoating remain
somewhat unclear in the field of HIV, however uncoating is essential for reverse
transcription to occur.
Reverse Transcription and Integration
The viral enzyme, RT, converts viral RNA into cDNA using host nucleotides
(Figure 2-step 4). Since RT has very little to no proofreading ability, many errors result
from this process. The end result from reverse transcription is the pre-integration
complex (PIC). The PIC has been shown to be associated with the viral proteins NC, MA,
RT, IN, and Vpr[5-7].

The nascent viral DNA can then be carried into the host cells’ nucleus through the
nuclear pore complex (NPC) (Figure 2-step 5). Viral CA has been demonstrated to be a
key determinant in nuclear import of the viral PIC, suggesting a connection between
uncoating and nuclear import[8]. In addition, several cellular proteins (Nup153, Nup358,
and TNPO3) have been shown to interact with HIV-1 CA to facilitate nuclear import of
the PIC[9-12].
The viral IN facilitates the joining of HIV DNA with host cell DNA forming an
integrated provirus (Figure 2-step 6). IN does this by essentially nicking the DNA to
allow for HIV-1 to insert itself, establishing life-long infection. The provirus may ‘hide’
and remain inactive (or latent) in the host cell genome for extended periods of time.
Transcription and Translation
The viral Tat protein is essential for successful transcription of the integrated
provirus (Figure 2-step 7). Tat operates by recruiting host cellular factors such as RNA
Pol II to the TAR element to facilitate transcription elongation. Once viral DNA is
transcribed into mRNA, it is carried out of the nucleus by cellular proteins and the viral
protein Rev (Figure 2-step 8). Short mRNAs can easily move out of the nucleus through
the use of CRM-1, a host nuclear export protein, while longer mRNAs require Rev.
These mRNAs then serve as templates for translation through the use of the host cell
translation machinery (Figure 2-step 9).
Assembly and Budding
Viral proteins gather at the cell surface along with viral genome-length RNA for
assembly of new viral particles (Figure 2-step 10). Particle budding, facilitated by the

cellular endosomal sorting complex required for transport (ESCRT) machinery (Figure 2step 11), and release (Figure 2-step 12) is followed by maturation mediated by the viral
protease (Figure 2-step 13) to create a new virion for infection to spread to other CD4+ T
cells.

Figure 2: HIV-1 viral life cycle, antiretroviral therapeutics, and cellular restriction
factors. Reprinted with permission from[4].

Antiretroviral therapeutic targets
The HIV-1 life cycle provides several points of intervention, however only four of
the above-mentioned steps have been the targets of various drugs approved in the United
States to administer to HIV positive individuals. Since the initiation of highly active
antiretroviral therapy (HAART), morbidity and mortality accompanying HIV-1 infection
and AIDS has dwindled[13]. HAART typically includes a combination of three drugs to
suppress viral replication and reduce viral loads in the plasma to allow the immune
system to rebuild[14-16]. The success of HAART results in part due to the diminished
likelihood of choosing virus clones with several mutations and conferring resistance to a
three-antiretroviral-drug regimen[17]. Nevertheless, as the virus continues to evolve and
escape, novel HIV-1 treatments will continuously be desired.
There are currently twenty-four Food and Drug Administration (FDA)-approved
drugs available that can be divided into six classes based on their mechanism of action:
(1) nucleoside-analog reverse transcriptase inhibitors (NRTIs), (2) non-nucleoside
reverse transcriptase inhibitors (NNRTIs), (3) integrase inhibitors, (4) protease inhibitors,
(5) fusion inhibitors, and (6) coreceptor antagonists[17]. The HAART regimen usually
comprises an NRTI, NNRTI, and a protease inhibitor[4]. When only one of the viral
proteins is targeted, the virus can simply attain mutations to acquire resistance to that
drug. However, the use of combinational drug therapy targeting multiple viral proteins
reduces the possibility that the virus will develop resistance.
Viral Entry and Fusion Inhibitors (Figure 2-Step 1 and 2)

HIV-1 entry and fusion inhibitors work by inhibiting the interaction between
envelope glycoproteins and the target cell. Crystallographic studies have suggested that
upon CD4 receptor engagement, gp120 undergoes tremendous conformational
modifications, and CD4 binds gp120 between the inner and outer domains in a conserved
hydrophobic pocket[18]. Therefore, small molecule inhibitors that mimic CD4 and
extend further into the conserved binding cavity on gp120 may increase the affinity for
gp120 leading to the production of clinically suitable inhibitors[19].
Generally, antibodies against gp120 fail to neutralize HIV-1 and are strain
specific. However, one group of researchers was able to redesign gp120 to disguise sites
external to the CD4-binding site[20, 21]. Using this construct along with peripheral
mononuclear cells from AIDS patients, Wu et al. isolated B cell clones that created
antibodies capable of broad neutralizing activity by engaging the CD4-binding site.
Additionally, peptides derived from gp41 N- or C-terminal sequences that disrupt
membrane fusion elicit antiviral activity[22, 23]. Enfuvirtide (Fuzeon) derived from the
C-terminus has been approved for therapeutic use, however its use is restricted due to the
requirement for multiple daily injections of the drug. Resistance mutations in gp41 have
also limited the use of Fuzeon clinically.
Reverse Transcription Inhibitors (Figure 2-Step 4)
NRTIs and NNRTIs inhibit DNA polymerization and are a part of HAART.
NRTIs mimic natural 2’-deoxyribonucleoside 5’-triphosphates (dNTPs) to become
incorporated into the viral DNA by RT[4]. They act as chain terminators because NRTIs
do not have the 3’-hydroxyl group required for successive nucleotide incorporation.

Unfortunately, viral resistance to NRTIs is common. Thymidine analogues, such as 3’azido-3’-deoxythymidine (AZT), have allowed for mutant RTs to develop that acquired
the capacity to eliminate the incorporated drug from the primer strand[24, 25].
NNRTIs act as allosteric inhibitors to induce conformational changes that form a
flexible binding pocket in the RT active site[26, 27]. Drug binding likely arises as a result
of interactions between aromatic side chains of Tyr181 and Tyr188 and the NNRTI, such
as nevirapine[26]. Viral resistance has been associated with mutations that restrict the
movement of Tyr188[4]. Newer NNRTIs, etravirine and rilpivirine, contain intrinsic
flexibility that allows for high-affinity binding to the mutant RT that has evolved from
first-generation NNRTIs[28].
IN Strand Transfer Inhibitors (INSTIs) (Figure 2-Step 6)
Raltegravir is a clinically approved HIV-1 INSTI that inhibits DNA strand
transfer activity[29]. INSTIs engage the bound metal ions in the IN active site to
somewhat effect their positioning, and the halogenated benzyl groups of INSTIs interact
with the viral DNA and IN to eject viral DNA from the active site[29, 30]. These types of
inhibitors can also sterically prevent target DNA binding to the IN active site[31, 32].
Lentiviruses prefer to integrate within active genes because of an interaction
between IN and LEDGF, a cellular chromatin-binding protein. Recently developed HIV1 IN inhibitors, known as LEDGINs, can mimic this interaction and impede proteinprotein binding[4, 33].
Protease Inhibitors (Figure 2-Step 13)

PR inhibitors are competitive inhibitors because they can bind to the active site of
PR and inhabit the inhibitor envelope[4]. These drugs are designed to bind explicitly
within the PR binding groove and only make contact with residues absolutely required
for PR function. The idea is that resistance mutations in the viral PR would be highly
unfavorable because any mutation would abolish PR functional activity[4].
Cellular Restriction Factors of HIV-1
In addition to the clinically available drug therapies targeted at various steps of
the viral life cycle, complex organisms have evolved a collection of dominant,
constitutively expressed genes that suppress or block HIV-1 infection. These activities
fall outside the established definitions of innate and adaptive immunity, but provide
‘intrinsic immunity’ to allow effective defense from viral infection[34]. Restriction
factors are largely responsible for this intrinsic immunity by acting as the front line of
host defense against viral infection. The initial evidence of cellular restriction factors
originates in mice when Friend virus susceptibility factor 1 (Fv1) was discovered as an
inhibitor of murine leukemia virus (MLV)[35]. Eventually, similar activities were
discovered in other mammals, including humans. In humans, restriction factor 1 (Ref1)
was found to inhibit N-tropic MLV (N-MLV) infection in a manner very similar to Fv1mediated restriction of MLV in mice[36].
A central idea to the biology of restriction factors is that HIV-1 usually escapes
their strong inhibitory activities in human cells, thereby permitting virus replication to
continue. In contrast, HIV-1 replication in nonhuman cells is generally limited by
restriction factors, marking these proteins as vital elements to viral host range and cross-

species transmission[37]. Since their initial discovery, several restriction factors have
been identified for HIV-1, such as TRIM5α, APOBEC3G, SAMHD1, and tetherin.
APOBEC3G (Figure 2-Step 4)
The discovery of Apolipoprotein B mRNA-editing enzyme, catalytic polypeptidelike 3G (APOBEC3G or A3G) arose as a result of understanding the function of the viral
protein Vif, which is required for HIV-1 replication in primary cells. Comparative
transcriptomics revealed that the human gene APOBEC3G could suppress the replication
of vif-deficient HIV-1[38]. A3G has cytidine deaminase activity that edits cytidines to
uridines to manipulate the nucleotide sequence[37]. In the absence of Vif, A3G becomes
packaged into nascent HIV-1 virions and is transported to new target cells by associating
with the viral RTC to deaminate cytidine residues in newly synthesized viral cDNA,
causing guanosine-to-adenosine hypermutation of the viral positive strand[39].
The molecular ‘arms race’ between virus and host allowed HIV-1, and other
lentiviruses, to acquire Vif, which counteracts A3G activity by recruiting A3G for
proteasomal degradation. This action results in the inability for A3G to be packaged into
newly assembling virions. The species-specific regulation of A3G by HIV and simian
immunodeficiency virus (SIV) Vif proteins is attributed to differences in amino acid
sequence of human and African green monkey (AGM) A3G, thus permitting recognition
by SIVAGM, but not HIV-1, Vif[40, 41]. It remains a challenge to tackle if disparity in
APOBEC3 can impact the course of HIV-1 infection in humans, however some findings
have proposed that higher levels of A3G, and the less potent APOBEC3F (A3F),
expression are associated with medical advantages[40].

SAMHD1 (Figure 2-Step 4)
The inhibition of HIV-1 infection in myeloid cells involves the cellular sterile
alpha motif domain HD domain-containing protein 1 (SAMHD1)[42, 43]. SAMHD1 is
highly expressed in myeloid-lineage monocytes, such as macrophages and dendritic cells.
SAMHD1 limits viral replication by hydrolyzing and reducing intracellular dNTPs,
which are essential for viral DNA synthesis[44]. Vpx and Vpr proteins of HIV-2 and SIV
from macaques (SIVMAC) and African green monkeys (SIVAGM) have been shown to
offset SAMHD1-mediated restriction of HIV-1 by targeting SAMHD1 for ubiquitinproteasome-dependent degradation[44-47]. HIV-1 does not contain a protein that can
antagonize SAMHD1, however HIV-1 can still replicate, although less efficiently, due to
the capacity of its RT to function under environments of low dNTP availability[44]. HIV1 stealthily and slowly replicates in non-cycling myeloid cells and sufficiently allows for
further transmission to activated cells[48]. This covert replication might avoid
recognition by the immune system.
Tetherin (Figure 2-Step 12)
Tetherin (also known as CD317 and BST2) was identified based on studies of the
Vpu accessory protein. In the absence of Vpu, HIV-1 is sensitive to a tethering
mechanism that traps nascent virions on the surface of infected cells and internalizes
them into endosomes[49-51]. Tetherin is astonishingly tolerant of mutations, including
replacement of entire tetherin domains with protein domains parallel in structure but not
sequence[52]. Tetherin has also been found in virions suggesting that either or both
membrane anchors are inserted into the lipid envelope of budding virions as they appear

from infected cells. Additionally, tetherin colocalizes with virions on the cell surface[5256]. The tetherin antagonist, HIV-1 Vpu, lessens the level of tetherin at the cell surface
by causing its internalization or delaying its advancement through the secretory
pathway[51, 57, 58]. Studies have also shown that Vpu can decrease the overall steadystate level of tetherin in cells when overexpressed[59]. The HIV-1 Vpu is species-specific
in that it is unsuccessful against tetherins from other animals, such as monkeys[60, 61].
TRIM5α (Figure 2-Step 3)
TRIM5α is an ~500 amino acid protein that is in the tripartite motif (TRIM)containing family of proteins[37]. It restricts by acting, in a species-specific manner, on
retroviral capsids following their entry into the cytoplasm. Generally, TRIM5α proteins
weakly hinder retroviruses in the same host species but not other species. For example,
human TRIM5α (TRIM5αhu) can inhibit N-MLV but not HIV-1, whereas TRIM5α from
old world monkeys can inhibit HIV-1[62-65]. At its C-terminus, TRIM5α has a
B30.2/SPRY domain that directly binds the retroviral capsid. Variable loops within the
SPRY domain have been shown to be vital determinants of antiretroviral specificity, and
even single amino acid substitutions in one of these segments of primate TRIM5α can
modify the capability to identify HIV-1 and SIV strains[66-69]. Retrotransposition events
have placed cyclophilin A (CypA) into the TRIM5 locus, replacing the SPRY domain, of
owl monkeys creating TRIMCyp[70-72]. TRIMCyp also potently inhibits HIV-1
infection through capsid binding and disruption[73-76].
Due to limited availability of experimental techniques to study the post entry
phase of HIV-1 where TRIM5α acts, it remains poorly understood how TRIM5-mediated

restriction occurs mechanistically. What is known is that TRIM5α directly binds
incoming HIV-1 capsids within fifteen minutes after the virus enters the cell[66, 77].
TRIM5α forms hexameric crystalline arrays in the presence of a higher-order six-fold
lattice of HIV-1 capsid[78]. This capsid-patterned oligomerization may trigger HIV-1
restriction by rhesus TRIM5α (TRIM5αrh) through a pattern recognition mechanism[79].
TRIM5α
Protein Domains and their function
The human genome contains roughly seventy genes of the TRIM family[80-83].
Most TRIM proteins are defined by the presence of the tripartite motif: a really
interesting new gene (RING) domain, one or two B-Box domains, and a coiled-coil (CC)
domain[81]. The tripartite motif is highly conserved, so the functional differences
amongst TRIM proteins can be accredited to their C-terminal domains. The most
common C-terminal domain is the PRY/SPRY, or B30.2 domain[81]. A depiction of
TRIM5αrh is shown in figure 3.
The RING domain is present at the N terminus of TRIM5α that contains a
putative E3 ubiquitin ligase activity essential for TRIM5α autoubiquitination and HIV-1
restriction[84]. The RING finger motif is a zinc-binding domain and defined by a
distinctive linear sequence of conserved cysteine and histidine amino acids[85][84, 86].
Substitution of alanine for the conserved cysteine15 in the RING-finger domain to
generate a C15A TRIM5α mutant depleted in vitro self-ubiquitination activity of
TRIM5α[84, 87]. Removal of the RING domain has been shown to affect proteasome
interactions by postponing the block in virus replication until after reverse transcription

has happened[88].
The B-box domain is another zinc-binding motif that occurs in two similar
orientations (B-box 1 and B-box 2) except for a distinct pattern of cysteine and histidine
residues[81]. TRIM5α only contains the B-box 2 domain, which is unique to members of
the TRIM protein family[81]. The B-box 2 domains of numerous TRIM proteins,
including TRIM5α, have been linked to protein-protein interactions, multimerization, and
subcellular localization[89]. Disruption of TRIM5αrh or TRIM5αhu B-box 2 domain
antagonizes the ability of these proteins to mediate retroviral restriction[66, 90, 91]. The
B-box domain of TRIM5α promotes cooperative CA binding by mediating TRIM5α selfassociation[89].
The coiled-coil (CC) domain has been identified as important for the formation of
homo-oligomers, which is essential for antiviral activity[92]. The CC domain is chiefly
comprised of alpha helices and is necessary for the development of TRIM5 dimers, which
form the building blocks for higher order assembly[81, 93]. Deletion of the CC region
has also been shown to avoid stable binding of the retroviral CA protein[77].
The C-terminal SPRY domain of TRIM5α plays a crucial role in retroviral
restriction by identifying certain determinants in the retroviral capsid and directly binding
the capsid[65]. The SPRY domain has three variable loops evolved to recognize specific
sites in the retroviral capsid[67, 68, 94, 95]. This results in species-specific retroviral
restriction. Yap et al. demonstrated that a single amino acid change in the SPRY domain
of TRIM5αhu is sufficient to gain restriction of HIV-1 in a similar manner as TRIM5αr

Figure 3: Schematic representation of TRIM5αrh. (Above) Representation of the
various domains of TRIM5αrh: the RING, BBox, coiled-coil (CC), and B30.2/SPRY with
the indicated amino acid positioning of the Linker 2 (L2) region (amino acids 234-296).
A zoomed in portion of the L2 region (amino acids 263-278) represents the site of triple
alanine mutagenesis. (Below) The abilities of the indicated WT or L2 mutants to elicit
cytoplasmic body formation and mediate HIV-1 restriction.

Cytoplasmic Bodies and the Linker 2 Region
TRIM5α has been shown to localize to cytoplasmic growths of protein termed
‘cytoplasmic bodies’[65, 96], which functionally, in terms of restriction, remain relatively
unclear. Two previous studies have found that cytoplasmic body localization is not
required for restriction[66, 97]. In contrast to these studies, Campbell et al. has observed
that cytoplasmic bodies are dynamic, trafficking on microtubules, and form around
individual HIV-1 virions in restricted cells[96, 98]. These studies would alternatively
propose that cytoplasmic bodies are significant for interactions between TRIM5α and
incoming retroviral capsids during restriction.
Sastri et al. utilized a variety of TRIM5α truncation mutants to locate regions
required for cytoplasmic body localization[99]. From these studies the region between the
CC and SPRY domains, the linker 2 (L2) region, were found to contain residues that
mediate cytoplasmic body formation. Additionally, deletion of the L2 region of fulllength TRIM5αrh inhibited the formation of cytoplasmic bodies and HIV-1
restriction[99]. Furthermore, as shown in figure 3, scanning alanine mutagenesis
identified two segments of amino acids, KPK266-268AAA and RRV275-277AAA, in the
L2 region that cause a diffuse localization of TRIM5α and are unable to restrict HIV-1
compared to WT TRIM5αrh[99]. The other two mutants, TFH269-271AAA and
HKN271-273AAA have recently been shown by our lab to form more cytoplasmic
assemblies per cell than wild-type TRIM5αrh[100]. It appears that residues within the L2
region facilitate self-association of TRIM5αrh, and this ability to self-associate is
important for restriction. Indeed, previous studies have demonstrated that the L2 region

affects the ability of TRIM5αrh to multimerize in biochemical crosslinking
experiments[76, 90, 92, 101].
Self-association of TRIM5α
Self-association of TRIM5α involves dimerization, higher-order multimerization,
and assembly[78, 92, 101], all of which are necessary for retroviral restriction mediated
by capsid recognition.
Initially, it was thought that TRIM5α forms trimers[101], however more recent
studies suggest that dimerization is more likely[102]. These studies utilized a
recombinant TRIM5αrh protein (TRIM5-21R) containing the RING domain from the
related TRIM21 protein to demonstrate that chemically cross-linked dimeric TRIM5-21R
bound HIV-1 CA-NC assemblies better than monomeric TRIM5-21R[102, 103]. This
direct binding to retroviral capsid-like complexes occurred in the absence of other
mammalian proteins. The CC domain is required for the formation of TRIM5α
dimers[66, 81], contributing to the avidity of TRIM5α for the HIV-1 CA[62, 64, 70, 71,
104]. Deletion of the TRIM5αrh CC disrupts the interaction with HIC-1 CA-NC
assemblies and loses the ability to act as a restriction factor[77].
The B-box 2 domain has been shown to promote higher order self-association
between preformed TRIM5α dimers that is required for retroviral CA binding and
restriction[76, 89-92, 102, 103, 105-107]. Indeed, it has been shown that mutations in the
B-box 2 region of TRIMα decreased binding to HIV-1 CA suggesting that these
modifications affect capsid recognition by positioning or conformation of the SPRY
domain[106]. On the other hand, B-box 2 mutations in TRIMCyp abrogated HIV-1

restriction and CA binding compared to wild-type TRIMCyp[106]. Furthermore, a
recombinant protein containing the cyclophilin A domain from owl monkey TRIMCyp in
place of the SPRY domain of TRIM5αrh was created to determine if CA recognition
differences between TRIM5α and TRIMCyp was due to alterations between the
TRIMdomains[106]. B-box 2 domain mutations were introduced into this chimeric
protein however these did not affect the ability to bind HIV-1 CA-NC assemblies[106].
CypA has a higher affinity for the HIV-1 CA as compared to the SPRY domain,
suggesting that the B-box 2 domain is required to increase the interaction between the
SPRY domain of TRIM5αrh and HIV-1 CA. Additional studies have identified a
hydrophobic patch on the B-box 2 domain, and changes in this patch or the flanking
arginine 121 inactivated TRIM5αrh-mediated HIV-1 restriction[105]. The loss of
restriction observed in this study was linked with higher-order self-association and HIV-1
CA binding affinity. The RING domain has also been shown to be required for TRIM5α
higher-order self-association; ∆RING-TRIM5αrh can form dimers but cannot selfassociate in co-immunoprecipitation assays with wild-type TRIM5αrh[108]. Additionally,
the L2 region may contribute to the effectiveness of higher-order self-association since
multiple L2 mutations were found to dimerize well but had diminished efficiencies in
higher order association with wild-type TRIM5αrh[108]. The SPRY domain is not
required for higher order self-association[89].
The role of CC and L2 regions in TRIM5α Assembly
The finding that scanning alanine mutagenesis of the L2 region of TRIM5α can
increase or decrease assembly proposes that these mutations may be changing secondary

structural elements. Our lab has recently demonstrated that the α-helical content of the L2
region correlates to the ability to form cytoplasmic assemblies and restrict HIV-1[100].
The above-mentioned L2 mutations that displayed heightened cytoplasmic body
formation compared to wild type had higher α-helical contents than wild type[100]. In
contrast, mutations with decreased cytoplasmic body formation showed lower α-helical
contents than wild type. These findings were based on Circular dichroism (CD) studies of
both the CC and L2 regions. CD analysis utilizing synthetic peptides comprising only the
L2 region did not reveal α-helical secondary structure except in the presence of 10%
trifluoroethanol (TFE), which can stabilize α-helical structures, where the α-helical
content of L2 peptides correlated with their ability to assemble and restrict infection,
similarly to CCL2[100]. This implies that the L2 region of TRIM5αrh is not inherently αhelical in the absence of the CC domain, proposing that the presence of the CC domain
somehow stabilizes the helical content of the L2 region.
Further studies examining and assessing the L2 region α-helices in the context of
a helical wheel diagram (Figure 4), demonstrated that the N-terminal region displays a
distinct amphipathic α-helix with a hydrophobic face[100]. Indeed, the N-terminal 32
amino acids of the L2 region comprise a primary sequence consistent with the existence
of an amphipathic α-helix with a hydrophobic surface.

Figure 4: Helical wheel diagram of residues 263-285 of the N-terminal region of L2
on TRIM5αrh. This depiction illustrates two interfaces in the L2 region. One interface
principally comprises positively and negatively charged amino acids. The second
interface consists of uncharged polar and non-polar amino acids. The N-terminal region
displays a distinct amphipathic α-helix with a hydrophobic interface. Hydrophobic
residues are shown in green, acidic residues are shown in red, basic residues are shown in
blue, and polar residues are shown in yellow[100].

Proposed Models of TRIM5α Assembly
The Ganser-Pornillos Model (Figure 5)
Ganser-Pornillos et al. studied TRIM5 higher-order assembly using a TRIM5-21R
chimeric protein where the RING domain of TRIM21 replaces the RING domain of
TRIM5αrh because it effectively restricts HIV-1 replication and is simpler to purify than
wild-type TRIM5α[78]. This chimera spontaneously assembled into two-dimensional
hexagonal arrays corresponding in symmetry and magnitudes to retroviral capsids, and
this lattice formation does not require the SPRY domain[78]. However, TRIM5-21R
assembly did require protein dimerization mediated by the CC domain as well as the
surface exposed residue Arg121 in the B-box 2 domain[78]. Based on these results, the
author’s proposed a model for TRIM5α-mediated retroviral CA recognition that includes
CA binding to the SPRY domain, TRIM5α dimerization, and assembly of a hexagonal
lattice complementary to the CA lattice for avidity enhancement. Furthermore, this model
proposes that the L2 regions of neighboring parallel dimers self-associate to organize
TRIM5α assembly around the retroviral core.

Figure 5: The Ganser-Pornillos model of TRIM5α assembly. Recombinant TRIM521R spontaneously assembles into two-dimensional paracrystalline hexagonal lattices.
Binding to hexagonal arrays of the HIV-1 CA lattice triggers this assembly. TRIM5-21R
assembly does not require the SPRY domain, however, it does require an Arg121 residue
in the B-box 2 domain as well as protein dimerization. Additionally, the L2 regions of
neighboring parallel dimers self-associate to facilitate assembly around the HIV-1 core.
Reprinted with permission from[78].

The Sodroski Model (Figure 6)
Li et al. performed studies to further elucidate TRIM5α higher order selfassociation. Utilizing co-immunoprecipitation (CO-IP) assays, preformed TRIM5 dimers
were able to CO-IP with homologous dimers forming higher order complexes, however
this result diminished when the RING or RING-L1 domains were deleted, suggesting that
the RING domain is required for higher order assembly but not dimerization[108]. In
addition, TRIM5 dimers were able to CO-IP with heterologous dimers of closely related
TRIM proteins (TRIM6 and TRIM34) although these interactions were weaker than their
initial studies solely examining interactions of homologous dimers implying that higher
order assembly of TRIM5 is governed by determinants in TRIM5 dimers[108]. Similar
results were obtained when examining the role of the B-box 2 domain on higher order
self-association. Disruption of the CC domain or elimination of the L2 region abolished
TRIM5 higher order complex formation, which would support the idea that the formation
of dimers must occur for further TRIM5 self-association[108]. Notably, Li et al. revealed
that the SPRY domain of TRIM5α is not required for higher order complex formation as
deletion of the SPRY domain had only very minimal effects on higher order assembly. In
contrast, deletion or alteration of residues in the L2 region proximal to the CC domain
elicited efficient dimerization but not higher order assembly of TRIM5αrh[108]. The
author’s proposed a model suggesting that TRIM5 dimers, oriented in a parallel manner,
form higher order complexes through RING and B-box 2 interactions at one end of the
dimer and L2 regions at the other end of the dimer. The model suggests that TRIM5
forms a trimer of dimers that would allow for the formation of hexagonal arrays.

Figure 6: The Sodroski model of TRIM5α assembly. This model proposes that
TRIM5α forms trimeric associations with parallel symmetry. Higher order selfassociation appears to be mediated by interactions between the RING (yellow) and B-box
2 (red) domains at one end of the dimer, and the L2 (green) region facilitates the
formation of higher order complexes at the other end of the dimer. The SPRY (orange)
domain appears dispensable for higher order self-association. The CC domain is shown in
blue as a parallel dimer. Adapted from[100].

The Sanchez et al. Model (Figure 7)
Despite the findings mentioned above, the molecular details of TRIM
oligomerization and high-order assembly are still poorly understood. A recent report by
Sanchez et al. utilized biochemical and crystallographic analysis to determine that
TRIM25 forms an elongated antiparallel dimer[109], in contrast to the model proposed
by Ganser-pornillos et al. Human TRIM25 was used since it doesn’t tend to form highorder assemblies, allowing for simpler use in biochemical assays. Crystallographic
analysis of the TRIM25 CC domain and N-terminal half of the L2 region allowed
visualization of a symmetrical dimer folding back into a hairpin configuration, in which
the L2 region folds back and packs against alpha helix in the CC domain[109]. CC
residues appeared to form a long arm of each subunit, indicated as helix H1, while the L2
residues appeared to form a short arm (containing helix H2 and H3) where H3 packs
against an amphipathic platform formed by dimeric H1 interactions creating a 4-helix
bundle[109].
Sanchez et al. also analyzed secondary structures across TRIM family members
and determined that the presumed CC domains are fixed within an adjoining helix
roughly 110 residues in length throughout the TRIM protein family, suggesting that the
dimeric CC domain structure of other TRIM proteins (including TRIM5α) is conserved.
Structural comparisons between TRIM5α and TRIM25 through disulfide crosslinking
experiments determined that these two proteins have similar dimer constructions[109].
Through the experiments performed by Sanchez et al., it appears that each side of the
TRIM5α hexagon is one CC dimer implying that the threefold symmetry of the hexagon

resembles the RING and B-box 2 domains, and the twofold symmetry of the hexagon
corresponds to the SPRY domain[109]. These data suggest that the L2 region may
stimulate the formation of cytoplasmic bodies and restriction by a previously
unacknowledged mechanism.

Figure 7: The Sanchez et al. model of TRIM5α assembly. Two potential arrangements
of domain connectivity at the three-fold axes of the TRIM5α hexagonal lattice as
observed by the TRIM25 crystal structure. (A) Three dimers with loops (magenta)
connect the CC helices (green) and L2 (gray) by a fold-back mechanism. (B) Three
dimers where the adjacent subunits have swapped their short arms. RING and B-box
domains are not pictured. Reprinted with permission from[109].

Hypothesis
Proposed models of TRIM5α assembly, while speculative in nature, insinuate that
the L2 region increases self-association and capsid binding. Our lab sought out
conceivable mechanisms by which the L2 region might position the domains of
TRIM5αrh. We hypothesized that if the L2 region does not contribute to TRIM5αrh selfassociation, then the Bbox2 domain must contribute all of the self-association activity of
TRIM5α, and the only way in which a hexagonal assembly is intuitively possible in this
case is in the setting of an antiparallel dimer[100]. We envisioned that the amphipathic
helix in the N-terminal portion of the L2 region might fold back onto itself to form
favorable interactions with other hydrophobic residues in the L2 region[100].
Biochemical cross-linking and fluorescence resonance energy transfer (FRET) analysis
were utilized to distinguish between established models of TRIM5α assembly.

CHAPTER II
MATERIALS AND METHODS
Plasmids
The wild type TRIM5αrh plasmid was a kind gift from Dr. Joseph Sodroski
(Harvard school of Public Health). Polymerase chain reaction (PCR) utilizing primers
specific for the CCL2 region, and the PCR product was digested with BamHI and XhoI to
insert into pECFP-N1, pECFP-C1, pEYFP-N1, pEYFP-C1 (Clontech), which were also
digested with BamHI and XhoI (Figure 8). The resulting constructs included: YFPCCL2, CCL2-YFP, CFP-CCL2, and CCL2-CFP (Figure 13). A similar approach was
taken in order to generate the CFP and YFP fused to the CC or L2 regions alone. All
constructs were verified by sequencing and western blot to confirm expression of YFP
and CFP.

Clone

Vector

Enzymes

YFP-CCL2

pEYFP-C1

BamHI/XhoI

CFP-CCL2

pECFP-C1

BamHI/XhoI

CCL2-YFP

pEYFP-N1

BamHI/XhoI

CCL2-CFP

pECFP-N1

BamHI/XhoI

Figure 8: Plasmid Cloning for FRET.
Western blotting
Cell lysates from transfected 293Ts were prepared by lysing cells in 1X NP-40
lysis buffer containing a protease inhibitor cocktail (PIC) on ice for 15 minutes. This was
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followed by the addition of sodium dodecyl sulfate (SDS, final concentration of 1X SDS
and boiling of samples at 100°C for 10 minutes to allow for protein denaturation.
Equivalent amounts of protein were loaded onto a 10% polyacrylamide gel and subjected
to SDS-polyacrylamide gel electrophoresis (SDS-PAGE) at 100V. Subsequently, proteins
were transferred onto nitrocellulose membranes and probed with an anti-GFP primary
antibody and an IgG horseradish peroxidase (HRP) secondary antibody. Western blots
were identified using SuperSignal West Femto chemiluminescent substrate and a BioRad
Chemidoc system[100].
Coomassie Staining
Purified protein samples were prepared by adding 2X SDS (for a final
concentration of 1X SDS) and boiled at 100°C for 10 min. Equivalent amounts of protein
were loaded onto a 10% polyacrylamide gel and subjected to SDS-PAGE at 100V.
Afterwards, gels were fixed in a colloidal Coomassie fixative (45% methanol and 1%
acetic acid in Milli Q water) for 1 hour and exposed to Coomassie stain (170 g
ammonium sulfate, 1 g Coomassie G250, 0.5% acetic acid, and 34% methanol in Milli Q
water) overnight. The following day, gels were washed with deionized water to remove
excess stain and imaged with a BioRad Chemidoc system[100].
Glutaraldehyde Crosslinking
Cell lysates from transfected 293Ts were prepared by adding 100 µl of 1X lysis
buffer + PIC to each sample and incubated on ice for 30 minutes. The samples were then
spun down at 3,000 rpm for 1 minute to eliminate cellular debris and divided into 20 µl
aliquots for cross-linking. Lysates were incubated with 0, 1, 2, and 4 mM glutaraldehyde
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at room temperature for 5 minutes followed by saturation through the adding 2 µl of 1 M
glycine to each sample (including samples that did not contain glutaraldehyde). Then, 20
µl of 2X-SDS was added to each sample and boiled at 100°C for 10 minutes. The crosslinked proteins were then loaded onto 4%-to-15% gradient Tris-HCl gels for SDS-PAGE
and western blot analysis as described above. Purified proteins were treated in a similar
manner but without 1X lysis buffer + PIC, and Coomassie staining was used instead of
western blot analysis[100].
Fluorescence Resonance Energy Transfer (FRET)
Human embryonic kidney 293T cells were split into DeltaT dishes at 50%
confluency and transfected, utilizing polyethylenimine (PEI), with 375ng total of YFP- or
CFP-tagged CCL2 TRIM5αrh in various combinations (discussed later). After 24 hours,
FRET efficiency (E) was measured with a DeltaVision microscope equipped with a
CoolSNAP HQ digital camera using a 60x objective lens. FRET efficiency was
calculated by analyzing forty or more individual regions for each FRET pair using the
following equation:
E = IDA – a (IAA) – d (IDD)
IDA – a (IAA) + (G-d)(IDD)
where IDD is the intensity of fluorescence emission detected in the donor channel (470/30
nm) with 438/10 nm excitation; IAA is the intensity of fluorescence emission detected in
the acceptor channel with 559/27 nm emission and 513/12 nm excitation; IDA is the
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intensity of fluorescence emission detected in the “FRET” channel with 559/27 nm
emission and 438/10 nm excitation. The “a” and “d” cross-talk coefficients were
determined from acceptor-only or donor-only samples, respectively. The crosstalk
coefficients were calculated utilizing the following equations:
a = IDA
IAA

d = IDA
IDD
We obtained a “d” value of 0.393 for CFP and an “a” value of 0.275 for YFP. G was
calculated using a construct generously provided by Dr. Seth Robia, which contains 5
glycines flanked by CFP and YFP. YFP was progressively photo bleached while
measuring the increase in CFP intensity. Once YFP was completely photo bleached, we
measured the amount of donor recovery and determined G as the ratio of sensitized
emission to the corresponding amount of donor recovery, which was 3.02[100].

CHAPTER III
RESULTS
Mutations in the L2 region that enhance the formation of cytoplasmic assemblies
and HIV-1 restriction do not affect TRIM5α self-association
Previous data generated by Ganser-Pornillos et al. have revealed that TRIM5α
assembles into 2-dimensional hexagonal arrays as described above[78]. However, the
orientation of TRIM5α dimers in these hexagonal arrays remains poorly understood.
Various models of TRIM5α assembly, illustrated in figure 9 (left and middle), suggest
that the dimers are oriented in a parallel fashion. These models further suggest that the L2
regions of TRIM5α dimers make contact with the L2 regions of opposing TRIM5α
dimers in a manner that could enhance assembly by mediating the self-association of
TRIM5α dimers. These findings along with our previous data, led us to hypothesize that
mutations in the L2 region that enhance or reduce assembly would also affect the
capability of TRIM5αrh to self-associate. To test this hypothesis, we utilized biochemical
cross-linking experiments to measure the self-association of TRIM5αrh dimers and
determine if the L2 region can mediate self-association in vitro. Both purified CCL2
peptide and CCL2 YFP or CFP fusion proteins were utilized in these experiments.
At low concentrations of glutaraldehyde (1 mM), a dimer was readily detectable
with the CCL2 peptide (Figure 10). The dimer was also detected with TFH-AAA CCL2,
RRV-AAA CCL2, and HKN-AAA CCL2 peptides and displayed striking similarities to
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WT CCL2 peptide (Figure 10), suggesting that the ability of L2 to facilitate CC
dimerization and the ability of L2 to affect TRIM5αrh assembly are fundamentally
independent of each other. As increasing concentrations of glutaraldehyde were used (2
and 4 mM), a laddering pattern emerged, consistent with nonspecific cross-linking of
TRIM5α proteins. In all cases, and at all concentrations, we did not visualize any
development of the tetrameric and hexameric species that would be suggestive of
intrinsic self-association of CCL2 dimers[78, 108].
We also performed similar experiments with CCL2 fused to YFP, as described in
the materials and methods. Here, we transfected 293T cells with the various constructs,
collected the cell lysates, and subjected them to cross-linking experiments for western
blot analysis. The CCL2 fusion proteins were cross-linked into a dimeric form in the
presence of glutaraldehyde, similarly to recombinant CCL2 peptide experiments
mentioned above (Figure 11).
Furthermore, we assessed the ability of L2 to facilitate self-association in the presence or
absence of the CC domain. Again, this was done by cloning CC and L2 fragments alone
into a YFP vector and subjected to glutaraldehyde cross-linking experiments. These
experiments did not reveal any self-association activity of the L2 region alone, and no
dimerization of the CC domain alone was visualized at any concentration of
glutaraldehyde used (Figure 11). Therefore, it seems that the L2 region is not capable of
intrinsic self-association, but it does seem to influence the ability of the CC region to
dimerize. However, the ability of L2 to influence CC dimerization appears independent
from its ability to affect assembly, since mutations previously described to affect

assembly of TRIM5αrh formed dimers and higher-order multimers in cells. These data
suggest that the L2 region is imperative for CC-mediated dimerization, which has also
been demonstrated in previous studies[101].
In data generated previously in our lab, the RRV-AAA L2 mutant, which is
unable to form cytoplasmic assemblies or restrict HIV-1, was shown to bind to in vitroassembled HIV-1 capsids as efficiently as WT[100]. This proposes that the L2 region
does not directly increase the self-association properties of TRIM5αrh essential for capsid
binding, implying that the L2 region does not directly contribute to the self-association of
TRIM5αrh dimers[100].

Figure 9: Published models of TRIM5 assembly. The various models of TRIM5α
assembly are color-coordinated with the illustrated domain organization of TRIM5α.
(Left) The Ganser-Pornillos model suggesting a parallel dimer assembly where the L2
regions of opposing dimers make direct contact. (Middle) The Li and Sodroski model
also suggesting a parallel dimer assembly, however this model suggests the formation of
a trimer of dimers. (Right) The Sanchez et al. model suggesting antiparallel dimer
assembly where the L2 region folds back on itself to form favorable interactions between
the amphipathic helix at the N-terminus of the L2 region and hydrophobic residues
further downstream in the L2 region[100].

Figure 10: L2 mutations that enhance TRIM5αrh assembly and HIV-1 restriction do
not affect the ability of TRIM5αrh to self-associate. The indicated CCL2 peptides were
cross-linked at room temperature by using increasing amounts of glutaraldehyde for 5
min. The glutaraldehyde was saturated by the addition of 1 M glycine, and cross-linked
peptides were visualized by SDS-PAGE and Coomassie staining[100].

Figure 11: The L2 region influences the ability of the CC domain to dimerize. 293T
cells were transfected with the indicated constructs and cell lysates were cross-linked in
the presence of increasing concentrations of glutaraldehyde. The samples were then
saturated with 1 M glycine and subjected to SDS-PAGE and western blot analysis using
an anti-GFP primary antibody and IgG-HRP secondary antibody.

CHAPTER IV
RESULTS
FRET analysis reveals that TRIM5α forms antiparallel dimers
Consistent with our previous findings that demonstrate that the L2 region does not
directly affect self-association of TRIM5α dimers, a recent study by Sanchez et al.
reported the crystal structure of the TRIM25 CCL2 domain, which revealed that TRIM25
forms an elongated antiparallel dimer in which the L2 regions fold back along the helix
of the CC dimer[109]. Additionally, structural and biochemical data have revealed that
the CC domain and L2 region of both TRIM25 and TRIM5α form comparable
structures[109]. We therefore tested the possibility that the CCL2 fragments of TRIM5αrh
similarly form antiparallel dimers (Figure 9, right) using FRET analysis.
FRET efficiency measurements are utilized to determine if two fluorophores are
within a certain distance of each other. In order for these types of experiments to be valid,
the distance between fluorophores must be smaller than 10 nm. A general depiction of
how FRET operates is shown in figure 12[110]. The basic phenomenon of FRET is that a
donor group is excited at a specific wavelength (unable to excite the acceptor) and
absorbs the energy from this excitation. If the acceptor group is less than 10 nm away
from the donor, then the energy from the donor will be transferred to the acceptor. This
energy transfer leads to decreased donor fluorescence intensity and increased acceptor
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emission fluorescence intensity. In order energy transfer to occur, the excitation
wavelength spectrum of the acceptor group should overlap the emission wavelength
spectrum of the acceptor group. The most commonly used fluorescent protein FRET pair
is cyan fluorescent protein (CFP) and yellow fluorescent protein (YFP) since the CFP
emission spectrum significantly overlaps the YFP excitation spectrum, supporting a
strong FRET interaction.

Figure 12: A general depiction of the molecular FRET mechanism. Two proteins (X
and Y) are fused to YFP and CFP. The donor (CFP) is excited at the appropriate
wavelength, and if the acceptor (YFP) is in close enough proximity, measurable energy
will be transferred from donor to acceptor causing an increase in FRET efficiency.
Reprinted with permission from[110].

To distinguish between the various models of TRIM5α assembly, we created
CCL2 fusions to fluorescent YFP and CFP FRET pairs shown in figure 13. Both N- and
C- terminal CFP and YFP fusions to CCL2 were generated since FRET efficiency
displays a sixth-order dependence on the separation distance between fluorophores. By
producing all four possible CCL2 fluorescent protein constructs (YFP-CCL2, CFPCCL2, CCL2-YFP, and CCL2-CFP) we were able to investigate the relative orientation
of fluorophores in CCL2 dimers using ensemble FRET measured in 293T cells
transfected with various combinations of CCL2 CFP and YFP FRET pairs. The FRET
efficiency was then calculated, as described in materials and methods, and compared
amongst the various combinations of CCL2 YFP/CFP FRET pairs to differentiate
between parallel and antiparallel dimer orientations of the CCL2 domain from TRIM5αrh.
A schematic of the projected FRET efficiencies based on proposed models of
TRIM5α dimerization is illustrated in figure 14. In the case of a CCL2 parallel dimer, the
expected highest FRET efficiency would occur in the presence of CFP-CCL2 and YFPCCL2, and the expected lowest FRET efficiency would occur in the presence of CCL2CFP and YFP-CCL2. However, if CCL2 forms an antiparallel dimer, the highest FRET
efficiency would occur in the presence of CCL2-CFP and CCL2-YFP, and the lowest
FRET efficiency would occur in the presence of CFP-CCL2 and YFP-CCL2.

Figure 13: Schematic of constructs generated for FRET analysis. Constructs
containing N-terminal and C-terminal YFP and CFP fused to CCL2 of TRIM5αrh were
created. The generation of all four conceivable constructs allowed us to differentiate
between possible CCL2 domain orientations through analyses of all combinations of
FRET pairs[100].

Figure 14: Expected FRET efficiencies based on the proposed models of TRIM5α.
(Left) A parallel dimer orientation, as proposed in the Ganser-Pornillos and Sodroski
model of TRIM5α, would be expected to give the highest FRET efficiency when CFP
and YFP FRET pairs are on the N-terminus of the CCL2 domain and the lowest FRET
efficiency when CFP and YFP are on the N- and C-terminus. (Right) An antiparallel
dimer orientation, as proposed by Sanchez et al., would be expected to give the highest
FRET efficiency when CFP and YFP FRET pairs are on the C-terminus of the CCL2
domain and the lowest FRET efficiency when CFP and YFP are on the N-terminus[100].

When the FRET efficiencies of all possible CCL2 CFP/YFP FRET pairs were
compared, they suggested a pattern consistent with an antiparallel dimer that has been
previously described for TRIM25[100, 109]. The calculated FRET efficiencies are shown
in figure 16. At about 20%, the highest FRET efficiency corresponded to an orientation
where both fluorophores were at the C-terminus of CCL2 (CCL2-CFP and CCL2YFP)[100]. In contrast, the lowest FRET efficiency (at about 2%) was observed when
both fluorophores were at the N-terminus of CCL2 (CFP-CCL2 and YFP-CCL2)[100].
An intermediate FRET efficiency (5-10%) was revealed when fluorophores were at
opposite ends of CCL2 (CCL2-YFP/CFP-CCL2 or CCL2-CFP/YFP-CCL2)[100]. These
data are consistent with the expected FRET efficiency pattern of an antiparallel dimer
illustrated in figure 14. If a parallel dimer were predominant, then we would have
expected to see the highest FRET efficiency in the presence of the N-terminal fusions to
CFP and YFP. However, this was not observed suggesting that the CCL2 dimer has
antiparallel symmetry allowing the L2 region to fold back down the CC helix giving the
closest FRET pair configuration and, therefore, FRET efficiency[100].

Figure 15: Representative Images from FRET Experiments. Human embryonic
kidney 293T cells were split into DeltaT dishes at 50% confluency and transfected,
utilizing polyethylenimine (PEI), with 375ng total of YFP- or CFP-tagged CCL2
TRIM5αrh in various combinations. After 24 hours, FRET efficiency (E) was measured
with a DeltaVision microscope equipped with a CoolSNAP HQ digital camera using a
60x objective lens. FRET efficiency was calculated by analyzing forty or more
individual regions for each FRET pair. The scale bars are shown in the first row.

Figure 16: FRET analysis reveals that TRIM5α forms antiparallel dimers. The
indicated combinations of CCL2 FRET pairs were transfected into 293T cells, and
ensemble FRET efficiency was measured at 24 hours post-transfection. At least forty
different regions were analyzed for each FRET pair to determine the fluorescence
intensity of the donor, acceptor, and FRET channels. A P value of less than 0.001 was
determined*. Results are representative of three independent experiments.[100].

CHAPTER V
DISCUSSION
The FRET experiments described above support the observation that TRIM
proteins, specifically TRIM5αrh, form antiparallel dimers. Based on our studies and the
studies performed by Sanchez et al. we developed a homology model of the CCL2
fragment of TRIM5αrh utilizing the recently reported structure of the TRIM25 CCL2
dimer. As illustrated in figure 17, our molecular modeling of the CCL2 region reveals
intramolecular contacts critical for assembly and restriction[100]. Sanchez et al.
described three helices (H1, H2, and H3) in the L2 region:
Helix 1: H1 covers the complete CC domain and a small portion of the L2 region.
This appears to form the ‘long arm’ of each CCL2 subunit.
Helix 2: H2 interacts with H1 to create a hairpin or ‘kink’ in the L2 region that
mediates the folding back of the L2 region onto the long arm of the CCL2 dimer.
Helix 3: H3 docks against H1 of the CC domain to form a 4-helix bundle. H2 and
H3 appear to form the ‘short arm’ of each CCL2 subunit.
Similarly, our homology model indicates the presence of three α-helices in the L2 region
of TRIM5αrh that partake in important interactions in the antiparallel dimer (see figure
17). Mutations that abrogate assembly and restriction (KPK266-268AAA and RRV275277AAA) are shown in figure 17 in red, while mutations that enhance assembly and
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increase restriction (TFH269-271AAA and HKN271-273AAA) are depicted in green.
Our biochemical cross-linking studies of purified recombinant WT CCL2 and the L2
variants showed no differences in dimerization, and none of the four peptides produced
any species higher than a dimer (Figure 10). Additionally, cross-linking of just the L2
region or CC domain alone abolished dimerization (Figure 11). Interestingly, CD analysis
of the L2 region alone, performed previously in our lab, revealed that the L2 region is
disordered. Collectively, these data propose that the abilities of residues within the L2
region to facilitate CC domain dimerization and affect higher order self-association of
TRIM5αrh are fundamentally independent.
We believe that restriction and assembly mediated by TRIMαrh essentially
depends on H3 docking to H1 of the CC domain to form a 4-helix bundle. This is
supported by previous studies in our lab that revealed that the TFH and HKN mutations
display increased α-helical content in CCL2 dimers, while the RRV mutation had
decreased α-helical content[100]. Our studies looking at the dynamics of the RRV mutant
compared to the WT CCL2 dimer suggest that H3 is stabilized by interaction of the RRV
motif with H1[100].
These data support our idea that there are three separate aspects of TRIM5αrh selfassociation:
Dimerization: An antiparallel dimer is the basic unit of TRIM5α self-association.
Formation is governed by interactions in the center of H1 of the CC domain
(forming an amphipathic platform) and also by some elements of the L2 region.

This is supported by our inability to visualize dimeric species when just the CC
domain or L2 region alone are cross-linked
Higher order self-association: This component of TRIM5αrh self-association is
facilitated by the B-box 2 domain. This is consistent with structural studies
performed by Sanchez et al. along with our FRET analysis revealing that TRIM
proteins form antiparallel dimers[100, 109] because, in the context of an
antiparallel dimer, the only way to promote development of higher order
complexes of TRIM5αrh required for assembly of a hexameric lattice is if the Bbox 2 domain is situated at either end of the antiparallel dimer. Our observation
that L2 mutations do not alter higher order self-association in cross-linking
experiments further support this notion[100].
Assembly: Assembly is mediated by C-terminal elements in the L2 region, which
could have an influence on proper spacing of SPRY domains to recognize the
HIV-1 core. Indeed, Ganser-Pornillos et al. and Sanchez et al. have previously
suggested this idea. Previous data published from our lab further supports this by
showing that alterations of the L2 region affected assembly without affecting
capsid binding[99, 100]. These data suggest that the L2 region has a previously
unappreciated step in assembly of TRIM5αrh prior to binding the HIV-1
capsid[100].
Shortly after we published our findings that the L2 region contains determinants
important for antiparallel dimer formation and assembly, a study by Goldstone et al. was
published showing that TRIM5α forms an antiparallel dimer that permits binding to the

HIV-1 capsid lattice[111]. Their group determined the crystal structure of the B-box2 and
CC domain displaying the elongated antiparallel dimers of CC domains. As previously
hypothesized, the crystal structure reveals that the B-box2 domains can be positioned at
either end of the CC domain through interactions with a helix in the L2 region of the
opposing monomer[111]. From these structural studies, Goldstone et al. concluded that
the antiparallel symmetry of TRIM5α facilitate the proper positioning of N- and Cterminal domains, which promotes stable binding to the hexameric lattice of the HIV-1
viral core.
Based on the studies performed by our lab, Sanchez et al. and Goldstone et al., it
appears that the new ‘dogma’ of TRIM5α self-association is in the context of an
antiparallel dimer. This would argue against the models proposed by Ganser-Pornillos et
al. and Li et al. described earlier. Continued studies are important in order to understand
the molecular mechanism of L2-mediated self-association events, which may provide
insight into the precise mechanism of TRIM5αrh-mediated HIV-1 capsid disassembly to
allow for restriction process.

Figure 17: Model of the TRIM5αrh CCL2 dimer. The CC domains are colored orange.
The L2 regions are depicted in blue. Assembly- and HIV-1 restriction-disrupting
mutations (as previously described) are shown in red. Assembly- and restrictionenhancing mutations are illustrated in green. The three proposed helices, based off of
studies performed by Sanchez et al., are also indicated. The opposing monomer is a
lighter shade for simplicity[100].
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